Literature DB >> 27851913

Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer.

George Plitas1, Catherine Konopacki2, Kenmin Wu3, Paula D Bos4, Monica Morrow5, Ekaterina V Putintseva6, Dmitriy M Chudakov7, Alexander Y Rudensky8.   

Abstract

Regulatory T (Treg) cells reside in lymphoid organs and barrier tissues where they control different types of inflammatory responses. Treg cells are also found in human cancers, and studies in animal models suggest that they contribute to cancer progression. However, properties of human intratumoral Treg cells and those present in corresponding normal tissue remain largely unknown. Here, we analyzed features of Treg cells in untreated human breast carcinomas, normal mammary gland, and peripheral blood. Tumor-resident Treg cells were potently suppressive and their gene-expression pattern resembled that of normal breast tissue, but not of activated peripheral blood Treg cells. Nevertheless, a number of cytokine and chemokine receptor genes, most notably CCR8, were upregulated in tumor-resident Treg cells in comparison to normal tissue-resident ones. Our studies suggest that targeting CCR8 for the depletion of tumor-resident Treg cells might represent a promising immunotherapeutic approach for the treatment of breast cancer.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27851913      PMCID: PMC5134901          DOI: 10.1016/j.immuni.2016.10.032

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  43 in total

1.  Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma.

Authors:  Katjana Klages; Christian T Mayer; Katharina Lahl; Christoph Loddenkemper; Michele W L Teng; Shin Foong Ngiow; Mark J Smyth; Alf Hamann; Jochen Huehn; Tim Sparwasser
Journal:  Cancer Res       Date:  2010-10-05       Impact factor: 12.701

2.  Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome.

Authors:  Michael Gobert; Isabelle Treilleux; Nathalie Bendriss-Vermare; Thomas Bachelot; Sophie Goddard-Leon; Vanessa Arfi; Cathy Biota; Anne Claire Doffin; Isabelle Durand; Daniel Olive; Solène Perez; Nicolas Pasqual; Christelle Faure; Isabelle Ray-Coquard; Alain Puisieux; Christophe Caux; Jean-Yves Blay; Christine Ménétrier-Caux
Journal:  Cancer Res       Date:  2009-02-24       Impact factor: 12.701

3.  MiXCR: software for comprehensive adaptive immunity profiling.

Authors:  Dmitriy A Bolotin; Stanislav Poslavsky; Igor Mitrophanov; Mikhail Shugay; Ilgar Z Mamedov; Ekaterina V Putintseva; Dmitriy M Chudakov
Journal:  Nat Methods       Date:  2015-05       Impact factor: 28.547

Review 4.  Regulatory T cells in cancer immunotherapy.

Authors:  Hiroyoshi Nishikawa; Shimon Sakaguchi
Journal:  Curr Opin Immunol       Date:  2014-01-14       Impact factor: 7.486

5.  An immunosurveillance mechanism controls cancer cell ploidy.

Authors:  Laura Senovilla; Ilio Vitale; Isabelle Martins; Maximilien Tailler; Claire Pailleret; Mickaël Michaud; Lorenzo Galluzzi; Sandy Adjemian; Oliver Kepp; Mireia Niso-Santano; Shensi Shen; Guillermo Mariño; Alfredo Criollo; Alice Boilève; Bastien Job; Sylvain Ladoire; François Ghiringhelli; Antonella Sistigu; Takahiro Yamazaki; Santiago Rello-Varona; Clara Locher; Vichnou Poirier-Colame; Monique Talbot; Alexander Valent; Francesco Berardinelli; Antonio Antoccia; Fabiola Ciccosanti; Gian Maria Fimia; Mauro Piacentini; Antonio Fueyo; Nicole L Messina; Ming Li; Christopher J Chan; Verena Sigl; Guillaume Pourcher; Christoph Ruckenstuhl; Didac Carmona-Gutierrez; Vladimir Lazar; Josef M Penninger; Frank Madeo; Carlos López-Otín; Mark J Smyth; Laurence Zitvogel; Maria Castedo; Guido Kroemer
Journal:  Science       Date:  2012-09-28       Impact factor: 47.728

6.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.

Authors:  Tyler J Curiel; George Coukos; Linhua Zou; Xavier Alvarez; Pui Cheng; Peter Mottram; Melina Evdemon-Hogan; Jose R Conejo-Garcia; Lin Zhang; Matthew Burow; Yun Zhu; Shuang Wei; Ilona Kryczek; Ben Daniel; Alan Gordon; Leann Myers; Andrew Lackner; Mary L Disis; Keith L Knutson; Lieping Chen; Weiping Zou
Journal:  Nat Med       Date:  2004-08-22       Impact factor: 53.440

7.  Phenotypic analysis of tumor-infiltrating lymphocytes from human breast cancer.

Authors:  Y Chin; J Janseens; J Vandepitte; J Vandenbrande; L Opdebeek; J Raus
Journal:  Anticancer Res       Date:  1992 Sep-Oct       Impact factor: 2.480

8.  Control of effector CD8+ T cell function by the transcription factor Eomesodermin.

Authors:  Erika L Pearce; Alan C Mullen; Gislâine A Martins; Connie M Krawczyk; Anne S Hutchins; Valerie P Zediak; Monica Banica; Catherine B DiCioccio; Darrick A Gross; Chai-An Mao; Hao Shen; Nezih Cereb; Soo Y Yang; Tullia Lindsten; Janet Rossant; Christopher A Hunter; Steven L Reiner
Journal:  Science       Date:  2003-11-07       Impact factor: 47.728

9.  Regulatory T Cells in Tumor-Associated Tertiary Lymphoid Structures Suppress Anti-tumor T Cell Responses.

Authors:  Nikhil S Joshi; Elliot H Akama-Garren; Yisi Lu; Da-Yae Lee; Gregory P Chang; Amy Li; Michel DuPage; Tuomas Tammela; Natanya R Kerper; Anna F Farago; Rebecca Robbins; Denise M Crowley; Roderick T Bronson; Tyler Jacks
Journal:  Immunity       Date:  2015-09-01       Impact factor: 31.745

10.  Developmental stage, phenotype, and migration distinguish naive- and effector/memory-like CD4+ regulatory T cells.

Authors:  Jochen Huehn; Kerstin Siegmund; Joachim C U Lehmann; Christiane Siewert; Uta Haubold; Markus Feuerer; Gudrun F Debes; Joerg Lauber; Oliver Frey; Grzegorz K Przybylski; Uwe Niesner; Maurus de la Rosa; Christian A Schmidt; Rolf Bräuer; Jan Buer; Alexander Scheffold; Alf Hamann
Journal:  J Exp Med       Date:  2004-02-02       Impact factor: 14.307

View more
  227 in total

Review 1.  Unlocking the Complexities of Tumor-Associated Regulatory T Cells.

Authors:  Jaime L Chao; Peter A Savage
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

2.  Single-cell chromatin accessibility landscape identifies tissue repair program in human regulatory T cells.

Authors:  Michael Delacher; Malte Simon; Lieke Sanderink; Agnes Hotz-Wagenblatt; Marina Wuttke; Kathrin Schambeck; Lisa Schmidleithner; Sebastian Bittner; Asmita Pant; Uwe Ritter; Thomas Hehlgans; Dania Riegel; Verena Schneider; Florian Kai Groeber-Becker; Andreas Eigenberger; Claudia Gebhard; Nicholas Strieder; Alexander Fischer; Michael Rehli; Petra Hoffmann; Matthias Edinger; Till Strowig; Jochen Huehn; Christian Schmidl; Jens M Werner; Lukas Prantl; Benedikt Brors; Charles D Imbusch; Markus Feuerer
Journal:  Immunity       Date:  2021-03-30       Impact factor: 31.745

3.  Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cell-rich and exhausted T-effector microenvironment.

Authors:  Fathima Zumla Cader; Ron C J Schackmann; Xihao Hu; Kirsty Wienand; Robert Redd; Bjoern Chapuy; Jing Ouyang; Nicole Paul; Evisa Gjini; Mikel Lipschitz; Philippe Armand; David Wu; Jonathan R Fromm; Donna Neuberg; X Shirley Liu; Scott J Rodig; Margaret A Shipp
Journal:  Blood       Date:  2018-06-07       Impact factor: 22.113

4.  Potential effect of tumor-specific Treg-targeted antibodies in the treatment of human cancers: A bioinformatics analysis.

Authors:  Luigi Cari; Giuseppe Nocentini; Graziella Migliorati; Carlo Riccardi
Journal:  Oncoimmunology       Date:  2017-11-09       Impact factor: 8.110

5.  IL-27 confers a protumorigenic activity of regulatory T cells via CD39.

Authors:  Young-Jun Park; Heeju Ryu; Garam Choi; Byung-Seok Kim; Eun Sook Hwang; Hun Sik Kim; Yeonseok Chung
Journal:  Proc Natl Acad Sci U S A       Date:  2019-02-04       Impact factor: 11.205

6.  Tumour immunology: Interrogating intratumoral Treg cells.

Authors:  Lydia Shipman
Journal:  Nat Rev Immunol       Date:  2016-12-05       Impact factor: 53.106

Review 7.  Biological Consequences of MHC-II Expression by Tumor Cells in Cancer.

Authors:  Margaret L Axelrod; Rebecca S Cook; Douglas B Johnson; Justin M Balko
Journal:  Clin Cancer Res       Date:  2018-11-21       Impact factor: 12.531

8.  KLRG1 impairs regulatory T-cell competitive fitness in the gut.

Authors:  Holger Meinicke; Anna Bremser; Maria Brack; Klaudia Schrenk; Hanspeter Pircher; Ana Izcue
Journal:  Immunology       Date:  2017-06-20       Impact factor: 7.397

9.  Tumour-associated changes in intestinal epithelial cells cause local accumulation of KLRG1+ GATA3+ regulatory T cells in mice.

Authors:  Holger Meinicke; Anna Bremser; Maria Brack; Paulina Akeus; Claire Pearson; Samuel Bullers; Katrin Hoffmeyer; Marc P Stemmler; Marianne Quiding-Järbrink; Ana Izcue
Journal:  Immunology       Date:  2017-06-19       Impact factor: 7.397

Review 10.  The promise and challenges of immune agonist antibody development in cancer.

Authors:  Patrick A Mayes; Kenneth W Hance; Axel Hoos
Journal:  Nat Rev Drug Discov       Date:  2018-06-15       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.